Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery - 05/08/11
, David R. Van Wagoner, PhD b, A. Marc Gillinov, MD c, Eugene H. Blackstone, MD c, dRésumé |
Background |
Preoperative use of angiotensin-blocking drug therapy (ABDT) with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and its link to occurrence of postoperative atrial fibrillation (POAF), a common marker of poor outcomes after cardiac surgery, remain controversial.
Methods |
From 1997 to 2003, 10,552 patients underwent coronary artery bypass grafting with or without valve surgery. To adjust for differences of clinical characteristics between patients who received ABDT within 24 hours before surgery compared with those who did not, propensity score analyses were conducted.
Results |
Angiotensin-blocking drug therapy was prescribed in 4,795 (45%) before surgery, of which 1,725 (36%) developed POAF before discharge versus 1,908 (33%) of 5,757 patients who did not receive ABDT (unadjusted odds ratio 1.13, 95% CI 1.05-1.25, P < .01). In 6,744 propensity score–matched patients with well-balanced comorbidity profiles, ABDT was not associated with POAF (odds ratio 1.05, CI 0.95-1.16, P = .38). Stratified analysis within quintiles of propensity score and propensity-adjusted logistic multivariable regression confirmed these findings.
Conclusions |
In this large observational study, we found no evidence of an association between preoperative angiotensin blockade and the occurrence of POAF. Adequately powered randomized studies are needed to clarify the best strategy of perioperative ABDT in patients with and without guideline-based indications.
Le texte complet de cet article est disponible en PDF.Plan
| Research support: (1) Atrial Fibrillation Innovation Center (an Ohio Wright Center of Innovation), (2) Fondation Leducq (Atrial Fibrillation Research Alliance), and (3) grant RR024990 from the National Center for Research Resources (NCRR), National Institutes of Health (NIH). There were no industry support and no conflicts of interest. |
Vol 160 - N° 2
P. 329 - août 2010 Retour au numéro
Article précédent
- Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction—Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
- Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson, Magnus Janzon
- Comparison of the clinical outcome after pulmonary vein isolation based on the appearance of adenosine-induced dormant pulmonary vein conduction
- Seiichiro Matsuo, Teiichi Yamane, Taro Date, Mika Hioki, Keiichi Ito, Ryohsuke Narui, Shin-ichi Tanigawa, Tokiko Nakane, Yoshiyuki Hama, Michifumi Tokuda, Seigo Yamashita, Yasuko Aramaki, Keiichi Inada, Kenri Shibayama, Satoru Miyanaga, Hiroshi Yoshida, Hidekazu Miyazaki, Kunihiko Abe, Ken-ichi Sugimoto, Ikuo Taniguchi, Michihiro Yoshimura
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?